The ^{99m}Tc-MIP-1404 PSMA Uptake in the Isolated Paratracheal Lymph Node From the Prostate Adenocarcinoma

Justinas Jonusas, MS, *† Sigitas Tiskevicius, MD, PhD,‡ and Ernestas Janulionis, MD, PhD†

Abstract: The oncologist consulted a 56-year-old man after receiving prostatespecific antigen screening results. Prostate-specific antigen level during the screen time was 33 ng/mL. As a result, poorly differentiated prostate adenocarcinoma with a Gleason score of 9 (5 + 4) was diagnosed. SPECT/CT scan with 99mTc-MIP-1404 PSMA tracer was performed. The 99mTc-PSMApositive lesions were detected in the prostate, external iliac, obturator lymph nodes of the pelvis, para-aortic, and the right lower paratracheal space. The patient was prescribed androgen deprivation therapy and early chemotherapy with docetaxel (6 fractions), after which radiation therapy to prostate and seminal vesicles was planned.

Key Words: PSMA, SPECT/CT, prostate cancer, paratracheal nodes

(Clin Nucl Med 2022;47: 1101–1102)

Received for publication May 19, 2022; revision accepted July 27, 2022. From the *Laboratory of Cancer Epidemiology, †Department of Brachyterapy, and Department of Nuclear Medicine, National Cancer Institute, Vilnius, Lithuania.

Conflicts of interest and sources of funding: none declared. Correspondence to: Justinas Jonusas, MS, Laboratory of Cancer Epidemiology, National Cancer Institute, Santariskiu Str. 1, LT-08406, Vilnius, Lithuania. E-mail: justinas.jonusas@nvi.com.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. ISSN: 0363-9762/22/4712-1101

DOI: 10.1097/RLU.00000000000004384

REFERENCES

- 1. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-583.
- 2. Zhao Q, Yang B, Dong A, et al. ⁶⁸Ga-PSMA-11 PET/CT in isolated bilateral adrenal metastases from prostate adenocarcinoma. Clin Nucl Med. 2022;47: e101-e102.
- Braga Ribeiro AM, Pereira Lima EN, Garcia D, et al. Single adrenal metastasis from prostate cancer detected by ⁶⁸Ga-PSMA PET/CT and confirmed by biopsy: a case report. Clin Nucl Med. 2022;47:e61–e62.
- 4. Dang S, Pereira M, Singh N, et al. An unusual case of bilateral ureteric metastasis on PSMA PET-CT scan in carcinoma prostate. Clin Nucl Med. 2022;47: e203-e204.
- 5. Perez NE, Maryala S, Seren S, et al. Metastatic prostate cancer presenting as mediastinal lymphadenopathy identified by EUS with FNA. Gastrointest Endosc. 2007;65:948-949.
- 6. Yang Y-J, Seo M, Jeon H-J, et al. Metastatic prostate cancer initially presenting as chylothorax: a case report. Mol Clin Oncol. 2016;4:1009-1012.
- 7. Schmidkonz C, Cordes M, Beck M, et al. SPECT/CT with the PSMA ligand ^{59m}Tc-MIP-1404 for whole-body primary staging of patients with prostate cancer. *Clin Nucl Med.* 2018;43:225–231.
- 8. Schmidkonz C, Atzinger A, Goetz TI, et al. 99mTc-MIP-1404 SPECT/CT for patients with metastatic prostate cancer: interobserver and intraobserver variability in treatment-related longitudinal tracer uptake assessments of prostate-specific membrane antigen-positive lesions. Clin Nucl Med. 2020;45:105–112.
- 9. Schmidkonz C, Götz TI, Atzinger A, et al. ^{99m}Tc-MIP-1404 SPECT/CT for assessment of whole-body tumor burden and treatment of whole-body tumor burden and treatment of the control of with biochemical recurrence of prostate cancer. Clin Nucl Med. 2020;45: e349-e357.




FIGURE 1. The oncologist consulted a 56-year-old man after receiving prostate-specific antigen (PSA) screening results. The PSA level during the screen time was 33 ng/mL. T3 stage of disease was suspected during the digital-rectal examination. Prostate mpMRI was performed right after. PI-RADS 5 lesions were identified in the right peripheral zone. The systemic 12-needle biopsy was performed, which staged the disease as follows: poorly differentiated prostate adenocarcinoma with a Gleason score of 9 (5 + 4). The patient was referred for a whole-body MRI (WB-MRI) scan for the distant staging. WB-MRI confirmed prostate cancer in the prostate gland. In addition, the right side iliac lymph nodes were classified as suspicious for metastasis. No distant metastases were detected on WB-MRI. In addition, the patient was referred for the ^{99m}Tc-MIP-1404 PSMA SPECT/CT scan (Siemens Symbia T6 SPECT/CT). Fused pelvic SPEC/CT images demonstrate ^{99m}Tc-PSMA-positive lesion in the prostate (A and B), external iliac (C), and the obturator lymph nodes of the right pelvis (D). Moreover, there were tracer-positive lesions in the para-aortic and right lower paratracheal lymph nodes (E–G). As a result, the patient was prescribed androgen deprivation therapy and early chemotherapy with docetaxel (6 fractions), after which radiation therapy to prostate and seminal vesicles was planned. Usually, prostate cancer tends to metastasize to bones and pelvic lymph nodes. There have been reports of uncommon places where prostate cancer metastases have been observed with the PSMA PET/CT imaging. ²⁻⁴ On the other hand, there is a scarcity of data regarding prostate cancer metastases detected in the mediastinum. Only a few case reports have reported metastases to the mediastinal area. ^{5,6} It has been shown that SPECT/CT imaging with a ^{99m}Tc-MIP-1404 PSMA tracer (Progenics Pharmaceuticals, Inc, New York, NY) is accurate and has low interobserver variability. ^{7,8} Moreover, another study showed that this tracer strongly correlates with PS